RNA:NSD-Avidity Biosciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 29.51

Change

+0.27 (+0.92)%

Market Cap

USD 2.48B

Volume

0.72M

Analyst Target

USD 43.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.70 (+0.35%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

+9.97 (+0.97%)

USD 110.51B
MRNA Moderna Inc

-5.20 (-3.58%)

USD 57.87B
BNTX BioNTech SE

-3.92 (-4.08%)

USD 24.18B
ARGX argenx NV ADR

-1.34 (-0.35%)

USD 23.09B
ALNY Alnylam Pharmaceuticals Inc

+0.34 (+0.21%)

USD 20.25B
GMAB Genmab AS

-0.22 (-0.83%)

USD 18.17B
BGNE BeiGene Ltd

-3.80 (-2.28%)

USD 17.74B
RPRX Royalty Pharma Plc

-0.28 (-1.03%)

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.73 (-0.87%)

USD 15.32B

ETFs Containing RNA

GNOG:LSE Global X Genomics & Biote.. 5.24 % 0.00 %

-0.11 (-2.42%)

USD 6.38M
SURI Simplify Propel Opportuni.. 3.24 % 0.00 %

-0.59 (-2.42%)

USD 0.12B
PTH Invesco DWA Healthcare Mo.. 2.75 % 0.60 %

-0.59 (-2.42%)

USD 0.14B
IWC iShares Micro-Cap ETF 0.55 % 0.60 %

-2.22 (-2.42%)

USD 0.82B
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

-0.85 (-2.42%)

USD 0.01B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.24 (-2.42%)

USD 0.09B
XSSX:LSE Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

+10.85 (+-2.42%)

USD 0.05B
DXSP:F Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

+0.13 (+-2.42%)

USD 0.05B
DXSP:XETRA Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

+0.13 (+-2.42%)

USD 0.05B
MOON Direxion Moonshot Innovat.. 0.00 % 0.00 %

-0.22 (-2.42%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 226.08% 98% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 226.08% 98% N/A 98% N/A
Trailing 12 Months  
Capital Gain 152.22% 95% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 152.22% 95% A 97% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -13.54% 42% F 23% F
Dividend Return -13.54% 42% F 23% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.17% 78% C+ 56% F
Risk Adjusted Return -40.82% 35% F 23% F
Market Capitalization 2.48B 91% A- 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector